Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026

Mirum Pharmaceuticals director Saira Ramasastry exercised 5,000 vested options and immediately sold the resulting shares for $400,000 (weighted average $80.00) under a Rule 10b5-1 plan, leaving her with zero direct common shares but retaining 10,000 options. Operationally the company reported strong metrics: TTM revenue of $471.79M, TTM net loss of $41.42M, roughly +90.7% one‑year share gains, preliminary 2025 net product sales of ~$520M (above guidance), a 2026 sales forecast of $630–$650M, ~$392M in cash and investments and positive operating cash flow, and a proposed Bluejay Therapeutics acquisition expected to close imminently.

Analysis

Market structure: Mirum (MIRM) is the clear beneficiary of improving commercial execution—2025 net product sales ~$520M beat guidance and management now guides $630–650M for 2026, which should expand pricing power for LIVMARLI in orphan-cholestasis niches and pressure smaller peers without scale. The director’s option exercise-and-sell under a 10b5-1 plan is neutral-to-positive signal for liquidity (no insider accumulation) and likely won’t change supply materially; outstanding options (10k) preserve management upside. Bond/credit spreads should narrow modestly for Mirum if cash flow stays positive (cash ~$392M); biotech equity vols may compress after earnings and M&A close, reducing option-implied skews.

Risk assessment: Tail risks include regulatory reversal on label/indication, Bluejay acquisition failure or integration dilution, and payer reimbursement cuts that could erase a large portion of the 2026 upside; these are low-probability but high-impact within 3–12 months. Near term (days–weeks) volatility driven by deal-close headlines and month-end flows; medium term (quarters) dependent on realized 2026 sales and gross margin trends; long term hinges on pipeline readouts and sustained positive operating cash flow. Hidden dependency: revenue growth is concentrated in one product and is sensitive to a small number of prescribers and payers.

Trade implications: Favor idiosyncratic long exposure to MIRM sized 1.5–3% NAV with a sector-hedge to remove biotech beta; use 6–12 month call-spread structures to cap cost and target asymmetric upside (>30% in 12 months). Pair trades: long MIRM, short IBB (or XBI) dollar-neutral to neutralize market moves through the Bluejay close (expected within 30 days) and 2026 guidance confirmation (next 90 days). Use stop-loss triggers tied to operational thresholds (see decisions).

Contrarian angle: The market may misread the insider sale as loss of conviction; in reality it’s routine comp mechanics given retained options and positive cash flow. If Bluejay closes and FY26 midpoint (~$640M) is met, upside is likely underappreciated vs peers—expect 30–50% re-rating if margins and payer coverage hold. Conversely, rapid multiple expansion could be vulnerable to short-term mean reversion if guidance slips by >8% or cash drops below sensible runway thresholds.

Key Decisions for Investors

• Establish a 2%–3% NAV long position in MIRM (Mirum Pharmaceuticals) within 5 trading days, target 12-month return +35% and set an absolute stop-loss at -20% from entry or conditional stop if 2026 guidance midpoint is revised below $600M.
• Purchase a 6–12 month call spread sized 0.5% NAV: buy ATM 12-month calls and sell ~30% OTM calls to fund (e.g., buy ATM, sell 1.3x strike); this captures asymmetric upside if Bluejay acquisition closes and FY26 sales hit $630–650M while limiting premium outlay.
• Implement a dollar-neutral pair trade: long MIRM (1.5% NAV) vs short IBB (1.5% NAV) to hedge sector/systematic biotech risk through the Bluejay close (target 30–90 day horizon) and the next quarterly sales print.
• Halt increases and re-evaluate within 30 days if the Bluejay Therapeutics acquisition does not close or if cash & investments fall below $250M, or if quarterly net product sales print misses the $630–650M trend by >8% (material deterioration trigger).